Fintel reports that on March 27, 2025, Oppenheimer initiated coverage of Aurora Innovation (NasdaqGS:AUR) with a Outperform ...

The director of ‘The End’ discusses getting tips from Werner Herzog and how contemplating catastrophe can make us more human ...

Africa's economic landscape in 2025 is shaped by visionary leaders who have amassed wealth through diverse industries.

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) yesterday and set a price target ...

Oppenheimer analysts called the M&A rebound ... deal volume is just 2.4% higher than it was last year, while equity capital markets volumes—which show fundraisings from initial public offerings ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

Oppenheimer lowered shares of Opthea (NASDAQ:OPT – Free Report) from an outperform rating to a market perform rating in a research report released on Monday, MarketBeat reports. A number of other ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 5 undervalued ...

Amprius Technologies (NYSE:AMPX – Get Free Report) had its target price boosted by equities research analysts at Oppenheimer ...

Former investment advisors whose clients put more than $62 million into a Marietta man’s alleged $110 million Ponzi scheme must pay the SEC $1.4 million.

Those, so far, have failed to fuel activity. M&A has increased only 2.4% year-to-date, and equity capital markets rose 2.7%, Oppenheimer said.